echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first domestic product!

    The first domestic product!

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On December 21, the CDE official website indicated that the listing application of Roche vedotin for injection (Polatuzumab vedotin) is planned to be included in the priority review for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)


    Vibotuzumab is a first-in-class anti-CD79b ADC, which is composed of CD79 targeting monoclonal antibody Polatuzumab, cleavable linker and small molecule drugs


    Vibotuzumab mechanism of action

    Vibotuzumab was first approved by the FDA in June 2019 (trade name: Polivy), combined with bendamustine + Rituxan (rituximab) for the treatment of relapse or refractory that has received at least two previous treatments Adult patients with curative (R/R) diffuse large B-cell lymphoma (DLBCL)


    A previous phase Ib/II clinical trial of Vibotuzumab evaluated the efficacy of the drug in 80 patients with relapsed or refractory DLBCL


    In August of this year, the pivotal Phase III POLARIX trial of Vibotuzumab combined with R-CHP for the first-line treatment of DLBCL reached its primary endpoint


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.